Execs On The Move, February 2021
Executive Summary
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
You may also be interested in...
Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
Avacta Pursues Combination Therapy Approach Targeting Solid Tumors
Avacta CEO Alastair Smith talks to In Vivo about the company’s precision chemistry, immunotherapy and diagnostic programs.
Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports